Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
 Research Grants Program
-Medical and Scientific Advisory Council
 Recent Recommendations
 What is MASAC?
-All MASAC Recommendations
 MASAC Members
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library

 

 

 
All MASAC Recommendations
 

Below are treatment recommendations from NHF's Medical and Scientific Advisory Council (MASAC).

MASAC Document Number Board Approval Date Title
STANDARDS AND CRITERIA
132 3/24/2002 Standards and Criteria for the Care of Persons with Congenital Bleeding Disorders
TREATMENT RECOMMENDATIONS
87 10/25/1998 MASAC Recommendation on Plasma Transfusion Alternatives
106 11/12/2000 MASAC Recommendation Regarding the Use of Recombinant Clotting Factor Replacement Therapy
167 6/3/2006 MASAC Recommendation Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors
169 6/3/2006 MASAC Recommendation Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission
179 11/04/2007 MASAC Recommendation Concerning Prophylaxis
183 11/16/2008 MASAC Statement Regarding Use of Herbal or Homeopathic Products to Treat von Willebrand Disease
222 10/06/2013 MASAC Recommendations Regarding Physical Therapy Guidelines in Patients with Bleeding Disorders
218 10/06/2013 Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders
220 10/06/2013 MASAC Recommendation Regarding Prophylaxis with Bypassing Agents in Patients with Hemophilia and High Titer Inhibitors
221 10/06/2013 MASAC Recommendations on Administration of Vaccines to Individuals with Bleeding Disorders
MANAGEMENT ISSUES
115 6/9/2001 MASAC Recommendations Regarding Central Venous Access Devices Including Ports and Passports
128 11/17/2001 MASAC Recommendations for Hepatitis A and B Immunization of Individuals with Bleeding Disorders
147 11/9/2003 Transition Guidelines for People with Bleeding Disorders
162 6/4/2005 MASAC Recommendations on Use of COX-2 Inhibitors in Persons with Bleeding Disorders
211 6/22/2012 MASAC Recommendations Regarding Inhibitor Risk and Recombinant Factor VIII Concentrates
216 5/10/2013 MASAC Statement Regarding Inhibitor Risk of Factor VIII Concentrates
CLOTTING FACTOR PRODUCTS
31 3/30/1993 MASAC Statement on Phase IV Post Licensing Studies
37 8/2/1994 MASAC Recommendation Concerning Parvovirus Transmission by Clotting Factor Concentrates
73 11/2/1997 Recommendations Regarding Blood Safety Policies
99 6/10/2000 MASAC Resolution on Creutzfeldt-Jakob Disease, new variant CJD, and Plasma-Derived Coagulation Products
139 3/8/2003 MASAC Recommendations on the IQPP and QSEAL Programs of the Plasma Protein Therapeutics Association
140 3/8/2003 MASAC Recommendation on Reporting of Possible West Nile Virus Cases
158 11/7/2004 MASAC Recommendations Regarding Exposure to Blood Product Derivatives and Potential Risk of vCJD.
EMERGENCY CARE
113 3/4/2001 MASAC Recommendations on Improved Access to Emergency Medical Care for Persons with Inherited Bleeding Disorders
129 11/17/2001 MASAC Resolution Regarding Emergency Supply of Factor Concentrate
175 10/15/2006 Guidelines for Emergency Department Management of Individuals with Hemophilia
201 01/13/2011 MASAC Recommendation on Use of Emergency Medical Identification Devices for Children
INFECTIOUS DISEASE COMPLICATIONS
32 4/19/1993 MASAC Recommendation Concerning Retesting of HIV-Antibody Negative Persons
90 10/25/1998 MASAC Revised Recommendation Regarding Treatment of HCV in HIV Coinfected Individuals with Hemophilia and Other Inherited Bleeding Disorders
93 6/26/1999 MASAC Statement on Pregnancy Options for HIV-Discordant Couples
223 10/6/2013 MASAC Recommendations on Liver Biopsy in Individuals with Hemophilia
108 11/12/2000 MASAC Recommendation Regarding Treatment of AIDS Wasting
109 3/4/2001 MASAC Resolution Concerning Participation in AIDS Clinical Trials by HIV-Infected Persons with Bleeding Disorders
110 3/4/2001 MASAC Recommendation Concerning CMV Screening of Blood Products for Use in HIV-Positive Individuals with Hemophilia
119 6/9/2001 MASAC Recommendation Regarding Post HIV-Exposure Chemoprophylaxis (see also #123)
121 11/17/2001 MASAC Recommendations for Immunization of HIV-Infected Individuals
123 11/17/2001 MASAC Recommendations Regarding Hepatitis B, Hepatitis C and HIV Postexposure Chemoprophylaxis
154 11/9/2003 MASAC Recommendations Regarding the Use of Antiretroviral Therapy in the Treatment of HIV Infection
213 11/11/2012 MASAC Recommendations for Treatment of Chronic HCV Infection in Individuals with Hemophilia and Other Rare Bleeding Disorders
ORTHOPEDICS AND PHYSICAL THERAPY
102 11/12/2000 MASAC Recommendation Regarding the Need for Collaborative Effort to Collect Data Regarding Interventions to Prevent Joint Damage Secondary to Hemophilia
105 11/12/2000 MASAC Recommendation Regarding Prevention of Cryptosporidiosis in and the Use of Therapeutic Pools by HIV-Infected Persons
130 3/24/2002 MASAC Recommendation Regarding the Use of Therapeutic Ultrasound to Aid in Blood Resorption
194 06/26/2010 MASAC Recommendations Regarding Radionuclide Synovectomy
POLICY
40 8/2/1994 MASAC Resolution on Home Care Delivery Systems
73 11/2/1997 MASAC Recommendations Regarding Blood Safety Policies
94 12/21/1999 Resolution Regarding Consumer Participation in the National Notification System
101 6/10/2000 MASAC Recommendation Regarding Reimbursement for Treatment of Acquired Hemophilia
111 3/4/2001 MASAC Resolution Concerning the Development of Comprehensive Outcome Measures
136 11/2/2002 MASAC Standard on Disclosing Conflicts of Interest for Individuals Conducting Clinical Research on Bleeding and Clotting Disorders
140 3/8/2003 MASAC Resolution on Reporting of Possible West Nile Virus Cases
145 10/19/2003 MASAC Recommendation on Funding of the Office of Cellular and Gene Therapies
146 10/19/2003 MASAC Recommendation Regarding Medicaid Inpatient Clotting Factor Replacement Therapy Reimbursement for Hemophilia
148 11/9/2003 MASAC Resolution on NHF Educational Program for Fellows
149 11/9/2003 MASAC Recommendation on the World Health Organization Essential Drug List
152 11/9/2003 MASAC Recommendations Regarding the Inclusion of Thrombophilia in NHF Research and Educational Efforts
153 11/9/2003 MASAC Recommendation Concerning Reimbursement for Recombinant Clotting Factor Concentrates
159 3/12/2005 MASAC Recommendation Regarding Factor Concentrate Prescriptions and Formulary Development and Restrictions
166 10/30/2005 MASAC Resolution Regarding Preferred Drug Lists
184 11/16/2008 MASAC Consensus Statement Regarding the Use of Fresh Frozen Plasma for the Immediate Reversal of the Anticoagulant Effects and/or Bleeding Complications Associated with Oral Vitamin K Antagonists
188 11/16/2008 MASAC Recommendations Regarding Standards of Service for Pharmacy Providers of Clotting Factor Concentrates for Home Use to Patients with Bleeding Disorders
189 6/6/2009 MASAC Consensus Statement on Plasma Safety
191 6/6/2009 MASAC Recommendation for Ongoing CDC Surveillance for CJD
199 6/9/2010 MASAC Resolution on Blood Donor Deferral Policy
206 11/12/2011 MASAC Recommendations Regarding Rare Coagulation Factor Disorders
207 11/12/2011 MASAC Recommendations Regarding Non-sterile Alcohol Prep Pads
208 6/22/2012 MASAC Recommendation on Orphan Drugs
209 6/22/2012 MASAC Statement on Biosimilars
219 10/06/2013 MASAC Resolution on Need to Facilitate Dialogue Between HTCs and Payers to Improve Access to Care at HTCs
RESEARCH
15 5/28/1990 MASAC Resolution on Fetal Tissue Research
91 2/28/1999 MASAC Recommendation Regarding Risk of Germline Transmission in Gene Therapy Trials for Hemophilia
111 3/4/2001 MASAC Resolution Concerning the Development of Comprehensive Outcome Measures
136 11/2/2002 MASAC Standard on Disclosing Conflicts of Interest for Individuals Conducting Clinical Research on Bleeding and Clotting Disorders
137 11/2/2002 MASAC Recommendations for Conducting Gene Transfer Clinical Trials in Persons with Bleeding Disorders
144 10/19/2003 MASAC Statement on the Role and Responsibilities of the Principal Investigator in Bleeding Disorder Clinical Trials
160 3/12/2005 MASAC Recommendation on the Need for Long-Term Follow-Up of Hemophilic Dogs in Gene Transfer Studies
161 6/4/2005 MASAC Resolution on Stem Cell Research for Potential Cure of Bleeding Disorders
171 10/15/2006 MASAC Resolution on National Hemophilia Foundation Sponsorship of Gene Therapy and Novel Technologies Workshops
212 11/11/2012 MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia
214 11/11/2012 MASAC Recommendations on the NHF Genotyping Project for Persons with Hemophilia
WOMEN AND BLEEDING DISORDERS
77 2/21/1998 Recommendations Regarding Neonatal Intracranial Hemorrhage and Postpartum Hemorrhage
81 3/11/1998 Considerations for Developing Psychosocial Interventions for Women with Bleeding Disorders
93 6/26/1999 MASAC Statement on Pregnancy Options for HIV-Discordant Couples
119 6/9/2001 MASAC Recommendation Regarding Post HIV-Exposure Chemoprophylaxis
122 11/17/2001 MASAC Recommendations Concerning the Use of Antiretroviral Drugs During Pregnancy to Prevent Transmission of HIV to the Infant
150 11/9/2003 MASAC Recommendations on the Use of Blood Products during Pregnancy and Testing for Parvovirus B19
180 6/15/08 MASAC Endorsement of the NHLBI Consensus Guidelines on the Diagnosis and Treatment of von Willebrand Disease
192 11/01/09 MASAC Guidelines for Perinatal Management of Women with Bleeding Disorders and Carriers of Hemophilia A and B
196 06/26/10 MASAC Resolution Regarding the Treatment of von Willebrand Disease
197 06/26/10 Recommendations Regarding Girls and Women with Inherited Bleeding Disorders